Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.36 |
| ▸ | MET | P08581 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | F2 | P00734 | 2/20 | 0.34 |
| ▸ | PLAU | P00749 | 2/20 | 0.34 |
| ▸ | ELANE | P08246 | 2/20 | 0.34 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.34 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.34 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3604564 | 0.90 | ELANE (0.40) | TSHRTDP1MAP2K4METALDH1A1 | |
| SCHEMBL31190618 | 0.85 | MET (0.38) | TDP1L3MBTL1MAP2K4METALDH1A1 | |
| SCHEMBL3600765 | 0.85 | MAP2K4 (0.37) | L3MBTL1MAP2K4METALDH1A1LMNA | |
| SCHEMBL3598244 | 0.85 | MET (0.38) | TDP1L3MBTL1MAP2K4METALDH1A1 | |
| SCHEMBL3610439 | 0.83 | MAP2K4 (0.36) | L3MBTL1MAP2K4METALDH1A1LMNA | |
| SCHEMBL3597479 | 0.82 | MAP2K4 (0.35) | TSHRL3MBTL1MAP2K4METALDH1A1 | |
| SCHEMBL13462468 | 0.81 | MAP2K4 (0.41) | MAP2K4ALDH1A1F2PLAUELANE | |
| SCHEMBL31190606 | 0.78 | MET (0.38) | MAP2K4METALDH1A1LMNAMAPT | |
| SCHEMBL6256806 | 0.76 | HTT (0.42) | MAP2K4METALDH1A1MAPTF2 | |
| SCHEMBL6389314 | 0.75 | ELANE (0.50) | L3MBTL1MAP2K4F2PLAUELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100063066-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA, INC. (US) | 2010-03-11 | — | — | US | disclosed |
| EP-2057168-A2 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2009-05-13 | — | — | EP | disclosed |
| WO-2008028141-A2 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2008-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063066-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | TSHR 2513/4885TDP1 1691/4885L3MBTL1 2066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.